专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

US20200222527A1 MERS-CoV Vaccine 审中-公开
公开(公告)号：US20200222527A1
公开(公告)日：2020-07-16
申请号：US16781433
申请日：2020-02-04
申请人： The Trustees of the University of Pennsylvania , Inovio Pharmaceuticals, Inc.
发明人： David Weiner , Karuppiah Muthumani , Niranjan Y. Sardesai
IPC分类号： A61K39/215 , A61K39/12 , C12N7/00
摘要： Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.

62. 发明申请

US20190085058A1 DNA Antibody Constructs And Method Of Using Same 审中-公开
公开(公告)号：US20190085058A1
公开(公告)日：2019-03-21
申请号：US16142457
申请日：2018-09-26
申请人： The Trustees of the University of Pennsylvania , Inovio Pharmaceuticals, Inc.
发明人： David Weiner , Karuppiah Muthumani , Seleeke Flingai , Niranjan Sardesai
IPC分类号： C07K16/10 , C07K16/32 , A61K48/00 , A61M37/00 , A61K39/00
摘要： Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.

63. 发明申请

US20180085451A1 Vaccines with CD40 Ligand as an adjuvant 审中-公开
公开(公告)号：US20180085451A1
公开(公告)日：2018-03-29
申请号：US15559432
申请日：2016-03-18
申请人： The Trustees of the University of Pennsylvania , INOVIO PHARMACEUTICALS, INC
发明人： David Weiner , Matthew Morrow , Megan Wise
IPC分类号： A61K39/39 , C07K14/705 , A61K39/145 , A61K39/21
CPC分类号： A61K39/39 , A61K39/0011 , A61K39/12 , A61K39/145 , A61K39/21 , A61K2039/53 , A61K2039/55516 , A61K2039/585 , A61P31/16 , A61P31/20 , A61P35/00 , C07K14/70575 , C07K14/70578 , C12N2710/20034 , C12N2740/16134 , C12N2760/16134 , Y02A50/412
摘要： Disclosed herein is a vaccine comprising an antigen and CD40L. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.

64. 发明申请

US20160256539A1 HIV-1 ENV DNA Vaccine Plus Protein Boost Delivered by EP Expands B- and T-Cell Response and Neutralizing 审中-公开
标题翻译：通过EP递送的HIV-1 ENV DNA疫苗+蛋白质增强可以扩增B-和T细胞应答和中和
公开(公告)号：US20160256539A1
公开(公告)日：2016-09-08
申请号：US15035793
申请日：2014-11-06
申请人： The Trustees of the University of Pennsylvania , Inovio Pharmaceuticals, Inc.
发明人： David Weiner , Karuppiah Muthumani , Megan Wise , Jian Yan , Kate Broderick
IPC分类号： A61K39/21 , C12N7/00 , C07K14/005
CPC分类号： A61K39/21 , A61K39/12 , A61K2039/53 , A61K2039/545 , A61K2039/57 , A61K2039/575 , A61K2039/70 , C07K14/005 , C12N7/00 , C12N2740/16122 , C12N2740/16134 , C12N2740/16171
摘要： The present invention is directed to an effective HIV vaccine will most likely require the induction of strong T-cell responses, broadly neutralizing antibodies (bNAbs), and the elicitation of antibody-dependent cellular cytotoxicity (ADCC). Previously, we demonstrated the induction of strong HIV/SIV cellular immune responses in macaques and humans using synthetic consensus DNA immunogens delivered via adaptive electroporation (EP). However, the ability of this improved DNA approach to prime for relevant antibody responses has not been previously studied.Here, we investigate the immunogenicity of consensus DNA constructs encoding gp140 sequences from HIV-1 subtypes A, B, C and D in a DNA prime protein boost vaccine regimen. Mice and Guinea pigs were primed with single and multi-clade DNA via EP and boosted with recombinant gp120 protein. Sera were analyzed for gp120 binding and induction of neutralizing antibody activity. Immunization with recombinant Env protein alone induced low-titer binding antibodies with limited neutralization breath. In contrast the synthetic DNA prime protein boost protocol was induced significantly higher antibody binding titers. Furthermore, sera from DNA prime-protein boost groups were able to neutralize a broader range of viruses in a panel of tier 1 clade B viruses as well as multiple tier 1 clade A and clade C viruses. Further investigation of synthetic DNA prime+adaptive EP plus protein boost appears warranted.
摘要翻译：本发明涉及有效的HIV疫苗很可能需要诱导强T细胞应答，广泛中和抗体（bNAb）以及诱导抗体依赖性细胞毒性（ADCC）。以前，我们通过使用通过自适应电穿孔（EP）递送的合成共有DNA免疫原，证明了在猕猴和人类中诱导强的HIV / SIV细胞免疫应答。然而，这种改进的DNA方法对相关抗体应答起始作用的能力尚未有研究。在这里，我们调查编码来自HIV-1亚型A，B，C和D的gp140序列的DNA启动蛋白增强疫苗方案的共有DNA构建体的免疫原性。小鼠和豚鼠用单次和多次进化枝DNA通过EP引发，并用重组gp120蛋白加强。分析血清中的gp120结合和中和抗体活性的诱导。用重组Env蛋白单独免疫诱导具有有限中和呼吸的低滴度结合抗体。相比之下，合成DNA初始蛋白增强方案诱导显着更高的抗体结合滴度。此外，来自DNA初始蛋白增强组的血清能够在1级进化枝B病毒以及多个1级进化枝A和进化枝C病毒的小组中中和更广泛的病毒。进一步调查合成DNA素+自适应EP加蛋白质提升似乎是有必要的。

65. 发明公开

US20240270805A1 MAGE-A VACCINES AND METHODS OF TREATMENT USING THE SAME 审中-公开
公开(公告)号：US20240270805A1
公开(公告)日：2024-08-15
申请号：US18588643
申请日：2024-02-27
申请人： The Wistar Institute of Anatomy and Biology
发明人： David Weiner , Elizabeth Duperret
IPC分类号： C07K14/47 , A61K39/00 , A61K39/39 , A61K45/06 , A61P35/00
CPC分类号： C07K14/4748 , A61K39/001186 , A61K39/39 , A61K45/06 , A61P35/00 , A61K2039/53 , A61K2039/55527 , A61K2039/55533 , A61K2039/572 , A61K2039/86 , A61K2039/876
摘要： Disclosed herein are compositions and methods for treating and/or preventing cancer in mammals, and in particular, vaccines that treat and provide protection against tumor growth.

66. 发明公开

US20240009300A1 DNA ENCODED NANOPARTICLES AND METHOD OF USE THEREOF AS A CORONAVIRUS DISEASE 2019 (COVID-19) VACCINE 审中-公开
公开(公告)号：US20240009300A1
公开(公告)日：2024-01-11
申请号：US18251620
申请日：2021-11-03
申请人： The Wistar Institute of Anatomy and Biology
发明人： Daniel Kulp , Ziyang Xu , David Weiner
IPC分类号： A61K39/215 , A61P31/14 , C07K14/165
CPC分类号： A61K39/215 , A61P31/14 , C07K14/165
摘要： Disclosed herein are nanoparticles comprising one or more SARS coronavirus 2 (SARS-CoV-2) Spike receptor binding domain (RBD) antigen and nucleic acid molecules encoding the same. Also disclosed herein is a method of treating a SARS-COV-2 infection or treating or preventing a disease or disorder associated therewith in a subject in need thereof, by administering the nanoparticles, or encoding nucleic acid molecules, to the subject.

67. 发明申请

US20210308243A1 OPTIMIZED SYNTHETIC CONSENSUS IMMUNOGENIC COMPOSITIONS TARGETING CHONDROITIN SULFATE PROTEOGLYCAN 4 (CSPG4) 有权
公开(公告)号：US20210308243A1
公开(公告)日：2021-10-07
申请号：US17264545
申请日：2019-08-01
申请人： THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
发明人： David Weiner
IPC分类号： A61K39/00 , C12N15/63 , A61K9/00 , A61P35/00
摘要： Provided herein is an immunogenic composition comprising a synthetic consensus antigen to chondroitin sulfate proteoglycan 4 (CSPG4) protein which is abundant in many cancers. Also disclosed herein is a method of treating a tumor associated pathology in a subject in need thereof, by administering the immunogenic composition to the subject.

68. 发明申请

US20210038711A1 EPSTEIN-BARR VIRUS NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAME 有权
公开(公告)号：US20210038711A1
公开(公告)日：2021-02-11
申请号：US16970084
申请日：2019-02-15
申请人： THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
发明人： David Weiner , Alfredo Perales Puchalt
IPC分类号： A61K39/245 , A61P31/22 , C12N15/79 , C07K14/05
摘要： Nucleic acid molecules and compositions comprising one or more nucleotide sequences that encode a consensus Epstein-Barr virus (EBV) antigen. Immunomodulatory methods and methods of inducing an immune response against EBV are disclosed. Method of treating infection by EBV and methods of treating or preventing a disease or disorder associated with EBV are disclosed. Modified consensus EBV antigens are disclosed.

69. 发明公开

US20230203133A1 DNA ANTIBODY CONSTRUCTS FOR USE AGAINST HEPATITIS B VIRUS 审中-公开
公开(公告)号：US20230203133A1
公开(公告)日：2023-06-29
申请号：US17997963
申请日：2021-05-06
申请人： The Wistar Institute of Anatomy and Biology
发明人： Kar Muthumani , David Weiner
IPC分类号： C07K16/08 , A61P31/20 , C12N15/63 , A61K45/06
CPC分类号： C07K16/082 , A61P31/20 , C12N15/63 , A61K45/06
摘要： Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Hepatitis B viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating a Hepatitis B virus infection in a subject using said composition and method of generation.

70. 发明申请

US20220098324A1 DNA-ENCODED BISPECIFIC T-CELL ENGAGERS TARGETING CANCER ANTIGENS AND METHODS OF USE IN CANCER THERAPUTICS 有权
公开(公告)号：US20220098324A1
公开(公告)日：2022-03-31
申请号：US17427434
申请日：2020-01-30
申请人： THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
发明人： David Weiner , Alfredo Perales-Puchalt , Kar Muthumani , Elizabeth Duperret
IPC分类号： C07K16/32 , C07K16/28 , A61P35/00
摘要： Disclosed herein are compositions comprising a recombinant nucleic acid sequence encoding a bispecific immune cell engaging antibody (DICE), a recombinant nucleic acid sequence encoding a bispecific T cell engaging (DBiTE) antibody, a fragment thereof, a variant thereof, or a combination thereof.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式